Vcare PharmaTech Ranked in Tier 1 of "Top 100 Chinese Innovative Pharmaceutical Seed Enterprises 2026" for Two Consecutive Years
Published Time:
2026-06-29 17:39
Source:
On June 26, the authoritative ranking of the "Top 100 Chinese Innovative Pharmaceutical Seed Enterprises 2026" (Seed 100 List) was officially released. Relying on its technological moat built by AI-driven original innovation, a complete independent R&D system, a tiered global innovation pipeline, marketed innovative drug achievements and comprehensive global patent portfolio layout, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) has once again been listed in Tier 1 of the ranking, marking its sixth consecutive year on the Seed 100 List.
Vcare PharmaTech has secured a spot on the Seed 100 List for six straight years since 2021. It entered Tier 1 for the first time in 2025 and retained this position this year. Its consistent listing and Tier 1 standing serve as high recognition of the company’s long-term dedication to developing innovative medicines and leading therapies, and fully validate its comprehensive strength and steady growth in technological innovation and translation, new drug research as well as clinical development.
AI Empowerment Fuels Differentiated Original Drug Design
Upholding independent incubation and original innovation, Vcare PharmaTech actively integrates cutting-edge technologies with new drug discovery, with a strategic focus on AI-enabled differentiated original molecular design. Artificial intelligence technology accelerates core R&D workflows including target identification, molecular design and candidate compound optimization, greatly boosting R&D efficiency and clinical success rates. This forward-looking strategy has built robust technological barriers across the entire innovative drug development cycle, and further consolidated the deeply collaborative industrial chain covering technology research, drug development and commercial manufacturing.
Accelerated Rollout of Innovation Pipeline; First Anti-Tumor Targeted Drug Granted Marketing Approval
Early June witnessed a landmark breakthrough in Vcare PharmaTech’s innovative drug development pipeline: VELMARTO® (Eratrectinib), the company’s self-developed Class 1 small-molecule targeted anti-tumor drug, obtained marketing approval from the NMPA. This milestone signals Vcare PharmaTech’s official transition from an R&D-focused biotech firm to an integrated enterprise covering both research and commercialization.
Meanwhile, the company’s innovation pipeline has delivered multiple key advances: one candidate drug has formally accepted NDA approval, several candidates are undergoing Phase II and Phase III clinical trials, and a batch of pre-clinical innovative drug programs are under continuous incubation. The tiered pipeline covers core therapeutic areas including oncology, cardiovascular and cerebrovascular diseases, as well as inflammatory and autoimmune disorders, forming a globally competitive product portfolio.
Address Unmet Clinical Needs via Differentiated R&D to Forge Global Competitiveness
Moving forward, Vcare PharmaTech will stay committed to its strategic mission of "addressing unmet clinical needs through differentiated innovation". The company will further expand its innovative drug pipeline, leverage the technical strengths of AI-powered original discovery, and speed up the research, translational development and commercial launch of more Class 1 innovative medicines. It aims to build a diversified innovative drug portfolio with solid technological barriers and outstanding clinical competitiveness across multiple disease areas, deliver superior treatment options for patients worldwide, and fuel high-quality growth of China’s pharmaceutical innovation sector.
About the Seed 100 List
The Seed 100 List selects enterprises representing the innovation potential of China’s pharmaceutical industry. Compiled by authoritative industrial media E Pharma Manager, the ranking adopts an evaluation framework centered on innovation foundation, innovation process and innovation output. Based on Clarivate’s Cortellis competitive intelligence, clinical trial data and Derwent Innovation patent database, evaluators analyze metrics including the number of granted patents, total patent citations, ongoing clinical trial programs, and approved/marketed new medicines to shortlist the top 100 innovative pharmaceutical enterprises.
Related News
19
2026
/
08
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) announced that the Phase II clinical trial of its self‑developed balanced, highly‑selective new‑generation JAK1 inhibitor VC005 Tablets for oral treatment of alopecia areata has completed enrollment of the first participant. This milestone marks the substantive clinical advancement of another indication of the drug in the autoimmune disease space, bringing expectations for novel therapeutic options for patients with alopecia areata.
View Details
17
2026
/
08
Recently, the Phase III clinical trial of VC005 Tablets, a next‑generation balanced high‑selectivity JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), for the oral treatment of ankylosing spondylitis (AS), has successfully completed enrollment of all subjects.
View Details
13
2026
/
08
Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) recently announced positive top‑line results from its multi‑center, randomized, double‑blind, placebo‑controlled Phase II clinical study evaluating orally‑administered VC005 Tablets, a self‑developed next‑generation balanced highly‑selective JAK1 inhibitor, in adult patients with non‑segmental vitiligo (NSV). This marks another positive top‑line outcome for VC005 Tablets in dermatological indications, following its Phase III program for moderate‑to‑severe atopic dermatitis (AD).
View Details
12
2026
/
08
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
August 6，the NMPA granted approval to Geneseeq’s PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The approval provides critical support for the precise identification and clinical medication of patients with NTRK fusion‑positive solid tumors.
View Details
17
2026
/
07
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) announced that the pivotal clinical trial of its self-developed Class 1 innovative drug VELMARTO® (generic name: Eratrectinib, research code: VC004) for patients with NTRK fusion-positive solid tumors who failed prior therapies has received official approval. This trial marks the first pivotal clinical study conducted by a China-originated NTRK innovative drug targeting pretreated patients with fusion-positive solid tumors. It signals that VELMARTO® has stepped into a systematic clinical research phase for treating drug-resistant solid tumors, further enriching the evidence-based medical data portfolio of the agent and delivering more robust treatment options for domestic patients with recurrent and drug-resistant NTRK fusion-driven solid tumors.
View Details
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn